Nuvation Bio (NYSE:NUVB) - Stock Analysis
Nuvation Bio (NYSE:NUVB) is a clinical-stage biopharmaceutical company focused on cancer treatment. The company recently reported a surprise statutory profit in Q1 2026, exceeding analyst expectations, and its lead product candidate, IBTROZI (taletrectinib), has received FDA approval and endorsements for ROS1-positive non-small cell lung cancer (NSCLC). Despite positive clinical developments and analyst upgrades, the company faces a shareholder investigation into corporate actions and competitive risks in the oncology market.
Eisai deal lifts Nuvation Bio (NYSE: NUVB) to Q1 2026 profit
Nuvation Bio (NYSE: NUVB) reported a strong Q1 2026, achieving a net income of $5.4 million, a significant turnaround from a $53.2 million net loss the previous year. This profitability was driven by a surge in total revenue to $83.2 million, largely attributed to initial U.S. sales of IBTROZI and a substantial upfront payment from an Eisai collaboration and license agreement. The company ended the quarter with a robust cash position of $533.7 million, supporting its ongoing pipeline advancements.
Nuvation Bio chief regulatory officer sells $184,279 in stock
Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), sold 36,750 shares of the company’s Class A Common Stock for $184,279 after exercising stock options. This transaction follows a significant 158.59% return in Nuvation Bio shares over the past year, with the stock deemed undervalued by InvestingPro analysis. The company has also reported recent developments including an amended license agreement for safusidenib and the European Medicines Agency's validation of a Marketing Authorization Application for taletrectinib, alongside positive analyst ratings.
Nuvation Bio Inc (NUVB): Take a Look at Glioma Revenue Potential
RBC Capital analysts have increased their price target for Nuvation Bio Inc (NUVB) to $20, reiterating an Overweight rating due to the significant revenue potential of its glioma drug candidate, safusidenib. The drug is currently in Phase 3 trials, with recent protocol updates reflecting alignment with US regulators and potential for swift approval in an underserved market. RBC Capital estimates safusidenib could generate up to $3.4 billion in US sales, addressing a critical unmet need in both high-grade and low-grade glioma treatment.
Nuvation Bio chief regulatory officer sells $184,279 in stock By Investing.com
Nuvation Bio's Chief Regulatory Officer, Kerry Wentworth, sold 36,750 shares of Class A Common Stock for $184,279 after exercising stock options. This transaction follows Nuvation Bio's shares delivering a 158.59% return over the past year, with the stock appearing undervalued according to InvestingPro. The company has also recently announced an amended license agreement for safusidenib and the European Medicines Agency's validation of taletrectinib's Marketing Authorization Application, leading to positive analyst revisions.
Nuvation Bio chief regulatory officer sells $184,279 in stock By Investing.com
Nuvation Bio's Chief Regulatory Officer, Kerry Wentworth, sold 36,750 shares of Class A Common Stock for $184,279 after exercising stock options. The sale was executed under a pre-arranged 10b5-1 plan. This transaction follows a significant 158.59% return for Nuvation Bio shares over the past year, and the company has recently made important strides with an amended license agreement for safusidenib and the European Medicines Agency's validation of taletrectinib.
Nuvation Bio chief regulatory officer sells $184,279 in stock
Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), sold 36,750 shares worth $184,279 after exercising stock options. This transaction follows Nuvation Bio's significant year-long performance and comes amidst positive analyst outlooks and strategic developments, including a new license agreement for safusidenib and regulatory validation for taletrectinib.
[144] Nuvation Bio Inc. SEC Filing
This SEC filing (Form 144) details the proposed sale of 50,000 shares of Nuvation Bio Inc. common stock, valued at $240,500.00, acquired through the exercise of stock options on April 17, 2026. The sale is to be conducted via Morgan Stanley Smith Barney LLC on the NYSE. The document confirms that no material adverse non-public information is known by the seller.
Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib
Nuvation Bio Inc. and Eisai have received EMA validation for their Marketing Authorisation Application for Taletrectinib, a treatment for advanced ROS1-positive non-small cell lung cancer. This approval follows an earlier licensing deal and targets a significant patient population in Europe. Taletrectinib is positioned as a potential standard-of-care due to its strong efficacy and safety profile.
Ibtrozi Prospects Asserts Nuvation Bio Inc. (NUVB) as one of the Best Healthcare Penny Stocks
Ibtrozi Prospects identifies Nuvation Bio Inc. (NUVB) as a top healthcare penny stock, citing a Buy rating and $12 price target from Truist Securities. The company's FDA-approved cancer drug, Ibtrozi, is performing strongly, generating $15.7 million in net product value last year. Nuvation Bio focuses on developing targeted oncology medicines and is also progressing with its Safu treatment for Glioma.
Nuvation Bio Executive Share Sale: CRO Kerry Wentworth Sells 200,000 Shares - News and Statistics
Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio, sold 200,000 shares of Class A Common Stock for approximately $904,000 on April 6. This transaction significantly reduced Wentworth's direct holdings by 79% but she still maintains a substantial economic interest through 700,000 stock options. Nuvation Bio is a clinical-stage biopharmaceutical company focused on cancer treatments.
Nuvation Bio officer Wentworth sells $903k in shares By Investing.com
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., sold 200,000 shares of Class A Common Stock for over $903,000 on April 6, 2026, and also exercised options to acquire 200,000 shares. Following these transactions, Wentworth directly owns 53,000 shares. The sale occurred after a significant 172% stock return over the past year, despite a 50% year-to-date decline, and InvestingPro analysis suggests the stock trades below its Fair Value.
Nuvation Bio officer Wentworth sells $903k in shares
Nuvation Bio's Chief Regulatory Officer, Kerry Wentworth, sold 200,000 shares of Class A Common Stock for $903,560 on April 6, 2026, while also exercising options worth $381,000 for an equal number of shares. Following these transactions, Wentworth directly owns 53,000 shares. Despite a 172% return over the past year, the stock is down 50% year-to-date but trades below its Fair Value according to InvestingPro.
Nuvation Bio officer Wentworth sells $903k in shares
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc, sold 200,000 shares of Class A Common Stock for over $903,000 after the stock saw a 172% return, despite a 50% year-to-date decline. Concurrently, Wentworth exercised options to acquire 200,000 shares. The company has also made significant strides with a license agreement amendment for safusidenib and regulatory advancements for taletrectinib, leading to positive analyst outlooks and raised price targets.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Pomerantz LLP is investigating Nuvation Bio Inc. (NYSE: NUVB) due to potential securities fraud or unlawful business practices, following a significant stock price drop. This drop occurred after Nuvation reported its Q4 and full-year 2025 financial results, revealing that a large percentage of patients discontinued IBTROZI therapy quickly, impacting near-term revenue. Investors affected by the 25.3% stock decline are encouraged to contact the firm for potential class action involvement.
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Nuvation Bio Inc. (NUVB) for potential securities law violations after the company's shares dropped 25.3% following its Q4 and full-year 2025 financial results. The decline was attributed to a significant portion of its early oncology therapy patient starts being in later-line treatment settings, leading to 75% of treatment discontinuations from these populations. Investors who suffered losses are encouraged to contact the law firm to discuss their rights.
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Nuvation Bio Inc. (NYSE: NUVB) for potential securities law violations after the company's shares fell by 25.3%. This investigation follows Nuvation Bio's Q4 and full year 2025 financial results, which revealed that a significant portion of early patient starts for its IBTROZI oncology therapy were in later-line treatment settings, leading to treatment discontinuations and impacting net product revenue. Investors who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights.
NUVB SEC Filings - Nuvation Bio Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Nuvation Bio Inc. (NUVB) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. It details the company's oncology business, financial position, and key agreements, enhanced with AI-generated summaries to explain the significance of each document. The article also lists recent filings with summaries, such as financial results, insider transactions, and a Q2 2025 earnings report.
NUVB SEC Filings - Nuvation Bio Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Nuvation Bio Inc. (NUVB) SEC filings, including annual 10-K reports, quarterly 10-Q statements, 8-K material event disclosures, and insider trading Form 4s. It details the company's oncology pipeline, financial performance, and specific insider transactions with AI-generated summaries to enhance understanding. Recent filings highlight positive Phase 2 data for safusidenib and the company's Q3 2025 financial results.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Pomerantz LLP is investigating Nuvation Bio Inc. (NYSE: NUVB) due to potential securities fraud or unlawful business practices. This investigation follows a 25.3% stock price drop on March 3, 2026, after Nuvation reported that 75% of discontinuations for its oncology therapy IBTROZI in 2025 were among later-line patient populations, impacting near-term revenue. Investors affected are encouraged to contact Pomerantz LLP.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Pomerantz LLP is investigating Nuvation Bio Inc. (NUVB) regarding potential securities fraud after the company's stock fell significantly. This investigation follows Nuvation's disclosure during its Q4 2025 earnings call, where management provided details on high treatment discontinuations for their oncology therapy IBTROZI among later-line patient populations, impacting near-term revenue. Investors are advised to contact the law firm regarding potential class action involvement.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Pomerantz LLP has launched an investigation into Nuvation Bio Inc. (NYSE: NUVB) following a significant drop in its stock price. The investigation concerns potential securities fraud or unlawful business practices, stemming from Nuvation's disclosure that a high percentage of patients discontinued its oncology therapy IBTROZI, impacting near-term revenue. Investors are encouraged to contact the firm for more information.
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Nuvation Bio Inc. (NYSE: NUVB) following a sharp decline in share prices. The investigation focuses on whether the company and its executives complied with federal securities laws after disclosures regarding high treatment discontinuation rates for its oncology therapy IBTROZI impacted revenue growth. Shareholders who suffered losses are encouraged to contact Johnson Fistel for more information.
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out
Johnson Fistel, PLLP is investigating potential claims against Nuvation Bio Inc. (NYSE: NUVB) on behalf of investors. This investigation follows the company's disclosure on March 2, 2026, regarding high treatment discontinuations among later-line patient populations for its oncology therapy IBTROZI, which led to a sharp decline in Nuvation Bio's shares. The law firm is examining whether Nuvation Bio and its executive officers complied with federal securities laws.
Nuvation Bio (NUVB) awards stock options and RSUs to company officer
Nuvation Bio Inc. reported that officer Makunje Moses was granted stock options for 224,439 shares and 50,761 restricted stock units (RSUs) of Class A Common Stock on February 27, 2026. These equity awards vest over several years, contingent on his continued service to the company. The stock options have an exercise price of $0.00 per share.
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch
Nuvation Bio (NUVB) reported $62.9 million in annual revenue for 2025, driven by the successful FDA approval and commercial launch of Ibtrozi (Taletrectinib) for ROS1-positive non-small cell lung cancer. The drug achieved rapid uptake, with 432 new patient starts by year-end, and the company is advancing its second lead program, safusidenib, for IDH1-mutant glioma, with Phase 3 trials initiated. Despite early revenue being influenced by late-line patients, Nuvation Bio anticipates improved revenue stability as first-line patient penetration increases and highlights Ibtrozi's differentiated clinical profile.
Form 8K Nuvation Bio Inc For: 2 March By Investing.com
This article reports on Nuvation Bio Inc.'s Form 8K filing for March 2nd. The filing is a standard SEC disclosure for significant corporate events. The brief mention indicates Nuvation Bio Inc. has submitted a regulatory document concerning an event on that specific date.
Nuvation Bio (NUVB) redeemable warrants removed from NYSE listing
Nuvation Bio Inc. (NUVB) has had its redeemable warrants delisted from the New York Stock Exchange. The NYSE filed a Form 25 notification, certifying that the warrants, exercisable for Class A common stock at $11.50 per share, were removed from listing and registration. Both the Exchange and Nuvation Bio complied with the rules governing the voluntary withdrawal of this class of securities.
IBTROZI launch lifts Nuvation Bio (NUVB) 2025 revenue while losses narrow
Nuvation Bio (NUVB) reported significant revenue growth in 2025, reaching $62.9 million, primarily driven by the launch of its ROS1 inhibitor, IBTROZI, which generated $24.7 million in product sales. The company also saw increased collaboration revenue and a narrowing of its net loss to $204.6 million, down from $567.9 million in 2024. Nuvation Bio ended the year with a strong cash position of $529.2 million and continues to advance its oncology pipeline, including the safusidenib program.
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Nuvation Bio Inc. reported strong financial results for the fourth quarter and full year 2025, driven by the rapid adoption of IBTROZI® (taletrectinib) for ROS1+ NSCLC. The company successfully started 216 new patients on IBTROZI in Q4 2025, totaling 432 new patient starts since its June 2025 launch. Nuvation Bio also announced an exclusive licensing agreement with Eisai for taletrectinib in Europe and other regions, and published positive Phase 2 study results for safusidenib in IDH1-mutant glioma.
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
Nuvation Bio has entered into an exclusive licensing agreement with Eisai for taletrectinib, an advanced oral treatment for ROS1-positive non-small cell lung cancer. This partnership grants Eisai development, registration, and commercialization rights in Europe and several other countries, excluding the U.S., China, and Japan where the drug is already approved. Nuvation Bio will receive an upfront payment of €50 million, up to €145 million in milestone payments, and tiered royalties from sales in the licensed territories.
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Eisai and Nuvation Bio have formed an exclusive licensing agreement for taletrectinib, an advanced ROS1-positive non-small cell lung cancer treatment, covering Europe and several other global territories. Under the agreement, Nuvation Bio will receive an upfront payment of EUR 50 million, up to EUR 145 million in milestone payments, and double-digit tiered royalties on sales. This partnership aims to expand the availability of taletrectinib, which is already approved in the U.S., China, and Japan, to a broader international patient population.
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
Nuvation Bio and Eisai have announced an exclusive licensing agreement for taletrectinib, an oral treatment for ROS1-positive non-small cell lung cancer, expanding its global reach beyond the U.S., China, and Japan. Eisai gains development, registration, and commercialization rights in Europe, the Middle East, Canada, Australia, and other territories, while Nuvation Bio retains U.S. rights and global development leadership. Nuvation Bio stands to receive up to €195 million in upfront and milestone payments, plus double-digit tiered royalties on sales in the licensed territories.
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
Nuvation Bio and Eisai have announced an exclusive licensing agreement for taletrectinib, a treatment for ROS1-positive non-small cell lung cancer, in Europe and other regions outside the U.S., China, and Japan. Nuvation Bio will receive an upfront payment of €50 million, up to €145 million in milestone payments, and double-digit tiered royalties on sales. This collaboration aims to expand the global reach of taletrectinib, which is already approved in the U.S., China, and Japan.
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
Nuvation Bio announced preliminary financial results for Q4 and full year 2025, reporting approximately $15.7 million and $24.7 million in IBTROZI net product revenue, respectively. The company successfully started 216 new patients on IBTROZI in Q4 2025, reaching a total of 432 new patient starts since its June 2025 launch. Nuvation Bio also provided a 2026 outlook, emphasizing continued growth for IBTROZI, advancement of its pipeline including safusidenib, and seeking new business development opportunities.
Nuvation Bio Inc.'s (NYSE:NUVB) institutional investors lost 5.2% last week but have benefitted from longer-term gains
Institutional investors, holding 57% of Nuvation Bio Inc. (NYSE:NUVB), experienced a 5.2% loss last week, though a 182% one-year return has mitigated some impact. The company's top five shareholders control 52% of the business, with CEO David Hung being the largest individual shareholder at 18%, and insiders collectively owning 25% of the company. Alongside retail investors and private equity firms, these groups significantly influence the company's share price and strategic decisions.
Nuvation Bio’s chief medical officer sells $1.17 million in stock
Dongfang Liu, the Chief Medical Officer of Nuvation Bio Inc. (NASDAQ:NUVB), sold 150,000 shares of Class A Common Stock for $1.17 million at a weighted-average price of $7.8217. Concurrently, Liu exercised options to acquire 150,000 shares at $2.93 each, highlighting a significant gain from the company's strong performance, with the stock up 204.9% in six months. Following these transactions, Liu directly holds 18,000 shares, and the company has a market capitalization of $2.85 billion.
Nuvation Bio officer Liu sells $155k in shares
Nuvation Bio Chief Medical Officer Dongfang Liu sold 20,000 shares of Class A Common Stock for $155,000, while also exercising options to acquire an equal number of shares for $72,200. This follows a strong third-quarter earnings report for Nuvation Bio, which surpassed revenue expectations and saw positive analyst coverage and increased price targets due to the successful commercial launch of its lead drug, Ibtrozi. These developments reflect growing confidence in Nuvation Bio's market position and future prospects.
Nuvation Bio officer Liu sells $155k in shares
Nuvation Bio's Chief Medical Officer, Dongfang Liu, sold 20,000 shares of Class A Common Stock for $155,000 across November 25-26, 2025, while also exercising options to acquire 20,000 shares for $72,200. This follows Nuvation Bio's strong third-quarter 2025 earnings, which significantly surpassed revenue expectations and led to positive analyst coverage with "Buy" ratings and increased price targets. The company's lead drug, Ibtrozi, and promising results from safusidenib contributed to growing investor confidence.
Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage
Nuvation Bio (NUVB) saw its stock price jump to a three-year high following positive analyst coverage. Investors reacted favorably to the bullish sentiment, pushing the stock upward. This surge indicates renewed confidence in the company's prospects among market participants.
Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025
Nuvation Bio (NUVB) stock surged approximately 50% after B. Riley Securities initiated coverage with a "Buy" rating and a $12 price target, driven by the successful launch of its lung cancer drug IBTROZI™ and strong Q3 2025 financial results. The company's leadership also presented at the Jefferies Global Healthcare Conference in London, further boosting investor interest. While the stock's valuation reflects high expectations, it is underpinned by tangible clinical data and explosive revenue growth for IBTROZI.
Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress
H.C. Wainwright analyst Robert Burns reiterated a Buy rating and a $10 price target on Nuvation Bio Inc. (NUVB) after the company announced the enrollment of 204 new patients in its IBTROZI cancer therapy trial for non-small cell lung cancer. The drug shows robust durability, with a 50-month median duration of response, and the company is set to receive a $25 million milestone payment from its partner Nippon Kayaku following regulatory approval in Japan. Nuvation Bio also reported increased revenue from collaboration and licensing agreements, primarily due to its partnership with Nippon Kayaku.
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Nuvation Bio Inc. (NYSE: NUVB) announced its financial results for the third quarter ended September 30, 2025, highlighting significant progress in its clinical programs and commercialization efforts. The company successfully initiated treatment for 204 patients with IBTROZI™ (taletrectinib) and reported a median Duration of Response of 50 months for the drug in ROS1-positive NSCLC. Nuvation Bio also enrolled the first patients in key studies for safusidenib and IBTROZI, while maintaining a strong cash balance of $549.0 million.
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Nuvation Bio reported its Q3 2025 financial results, highlighting successful commercialization of IBTROZI™ with 204 new patients initiated. The company also announced an updated median Duration of Response of 50 months for IBTROZI in ROS1+ NSCLC and progression in its safusidenib and NUV-1511 clinical programs. Nuvation Bio concluded the quarter with a strong cash position of $549.0 million.
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q3 Revenue $13.1M, vs. FactSet Est of $6.6M
Nuvation Bio Inc. (NUVB) reported its Q3 revenue at $13.1 million, significantly exceeding the FactSet estimate of $6.6 million. This financial update indicates a stronger performance than anticipated by analysts for the biotechnology company. The article provides recent news and financial data for Nuvation Bio, highlighting its clinical-stage pipeline and recent company announcements.
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Nuvation Bio announced its Q3 2025 financial results, highlighting the successful launch of IBTROZI™ (taletrectinib) with 204 new patients started, and an updated median Duration of Response (DOR) of 50 months for the drug in ROS1-positive NSCLC. The company also reported progress in its pipeline, including the enrollment of the first patient in a registrational study for safusidenib and the TRUST-IV phase 3 study for IBTROZI, while maintaining a strong cash position of $549.0 million.
Nuvation Bio Inc. (NYSE:NUVB) Receives $7.86 Consensus PT from Brokerages
Nuvation Bio Inc. (NYSE:NUVB) has received a consensus price target of $7.86 from brokerages, with several analysts issuing "buy" or "outperform" ratings and specific price targets. The company's stock recently dropped by 6.1%, and institutional investors hold a significant portion of its shares. Nuvation Bio is a clinical-stage biopharmaceutical company focused on oncology therapies, with lead product candidates NUV-868, NUV-1156, and a drug-drug conjugate platform, as well as NUV-1176.
Nuvation Bio’s (NUVB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Wedbush reaffirmed its "Outperform" rating on Nuvation Bio (NUVB) in a recent report. Several other analysts have also issued positive ratings with price objectives between $6.00 and $10.00. Institutional investors have significantly increased their holdings in Nuvation Bio, with hedge funds and other institutional investors owning 61.67% of the stock.
Nuvation Bio Surges on Japanese Approval of Ibtrozi for Lung Cancer
Nuvation Bio's stock surged after receiving Japanese approval for its lung cancer drug, Ibtrozi, for ROS1-positive non-small cell lung cancer. This approval is a significant regulatory win, with a $25 million milestone payment expected. Despite financial headwinds and negative margins, analysts see uplift potential if strategic execution aligns with market developments.
Nuvation Bio Says Japan Approves IBTROZI For ROS1+ Advanced Non-small Cell Lung Cancer Treatment
Nuvation Bio Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZI (taletrectinib) for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). This approval is part of an exclusive license agreement with Nippon Kayaku, which will commercialize IBTROZI in Japan. Nuvation Bio expects to receive a $25 million milestone payment in Q4 2025 upon the establishment of the reimbursement price in Japan.
